Ebos Group Limited · NZX:EBO
Ebos — Investor Presentation (April 2019)
24 slides from Ebos's investor presentation, Apr 30, 2019
Slide 1: Equity Capital Raising
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES For personal use only EQUITY CAPITAL RAISING 30 April 2019 NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES
Slide 2: Important Notice and Disclaimer
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES IMPORTANT NOTICE AND DISCLAIMER For personal use only The following notice and disclaimer applies to this investor presentation (Presentation) and you are therefore advised to read this carefully before reading or making any ot
Slide 3: Important Notice and Disclaimer
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES IMPORTANT NOTICE AND DISCLAIMER For personal use only Future performance Certain statements made in this Presentation are forward-looking statements. These forward-looking statements are not historical facts but rather are base
Slide 4: Important Notice and Disclaimer
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES IMPORTANT NOTICE AND DISCLAIMER For personal use only Disclaimer None of the underwriter, nor its or EBOS‘ respective advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, empl
Slide 5: ~NZ$150 Million Equity Raising
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES ~NZ$150 MILLION EQUITY RAISING EBOS Group Limited (“EBOS”) is the largest and most diversified Australasian marketer, wholesaler and distributor About EBOS of healthcare, medical and pharmaceutical products For personal use o
Slide 6: Business Snapshot
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES BUSINESS SNAPSHOT EBOS Group is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading For personal use only marketer and dist
Slide 7: Group Overview
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES GROUP OVERVIEW Diversification within Healthcare & Animal Care is a key signature of our approach For personal use only HEALTHCARE ANIMAL CARE COMMUNITY INSTITUTIONAL CONTRACT CONSUMER PRODUCT & VET RETAIL PHARMACY HEALTHCARE L
Slide 8: EBOS Executive Leadership Team
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES EBOS EXECUTIVE LEADERSHIP TEAM For personal use only Chief Executive Officer John Cullity CEO Animal Care & Chief Financial Chief Information Group Human Executive General CEO, Symbion General Counsel Consumer Brands Officer Of
Slide 9: Leading Market Positions
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES LEADING MARKET POSITIONS EBOS has leading market positions across the Group in particular in hospital pharmaceutical wholesale and community pharmaceutical wholesale in both Australia and New Zealand For personal use only Combi
Slide 10: EBOS' Financial Performance
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES EBOS’ FINANCIAL PERFORMANCE EBOS has delivered significant value to shareholders with a strong return on capital employed and consistent growth in EBITDA, earnings per share and dividends per share For personal use only 5 Year
Slide 11: Historical Financials
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES HISTORICAL FINANCIALS EBOS has delivered consistently strong cash flows and earnings growth For personal use only 250.1 Group CAGR: 228.2 45.7 +12.0% 207.7 42.2 182.3 39.0 Animal Care CAGR: +14.4% EBITDA (A$m) 158.9 34.6 26.7 H
Slide 12: EBOS' Track Record
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES EBOS’ TRACK RECORD EBOS has a proven track record of successfully completing strategic acquisitions and accretive capital works programs having deployed over A$600m since FY14 For personal use only Investments made (A$m) Over A
Slide 13: EBOS Strategic Approach
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES EBOS STRATEGIC APPROACH For personal use only Our Healthcare and Animal Care strategic focus is centred on Leading Market Disciplined Capital Investing for Growth Positions Management We aim to have positions of Two types of in
Slide 14: Investing for Growth: Capex
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES INVESTING FOR GROWTH: CAPEX Over the past five years, EBOS has invested ~A$160m, principally in its Healthcare distribution infrastructure to increase the Group’s capacity, reduce its cost to serve and improve productivity For
Slide 15: Investing for Growth: Acquisitions
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES INVESTING FOR GROWTH: ACQUISITIONS EBOS has a long history of successfully acquiring high quality businesses which have delivered attractive levels of growth For personal use only • Established capabilities to evaluate and exec
Slide 16: Use of Proceeds
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES USE OF PROCEEDS The proceeds from the placement will initially pay down bank debt and reduce gearing, For personal use only before being used for strategic acquisitions, organic growth initiatives and general corporate purposes
Slide 17: Equity Raising Overview
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES EQUITY RAISING OVERVIEW For personal use only Approximately NZ$150 million Placement of approximately 7.7 million new ordinary shares (“New Shares”) Placement Placement is to be underwritten at a fixed price of NZ$19.70 per
Slide 18: Timetable
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES TIMETABLE For personal use only Event Date Trading halt on NZX and ASX Tuesday 30th April 2019 Placement announcement Tuesday 30th April 2019 Placement completion announcement lodged with NZX / ASX and Wednesday 1st May 2019 EB
Slide 19: Key Risks & International Offer Restrictions
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES For personal use only Key Risks & International Offer Restrictions
Slide 20: Key Risks
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES KEY RISKS Risk Description For personal use only Product liability EBOS may, from time to time, experience product defects or other claims relating to its products or services. Defects in products that EBOS markets, sells or ex
Slide 21: Key Risks (Cont'd)
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES KEY RISKS (CONT’D) Risk Description For personal use only Regulatory risk and EBOS operates in a number of highly regulated industry segments, including in relation to the distribution and supply of pharmaceutical, medical and
Slide 22: Key Risks (Cont'd)
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES KEY RISKS (CONT’D) Risk Description For personal use only Future dividends and No assurance can be given in relation to the payment of future dividends. Future determinations as to the payment of dividends by EBOS will be at th
Slide 23: International Offer Restrictions
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES INTERNATIONAL OFFER RESTRICTIONS This presentation does not constitute an offer of shares (New Shares) of EBOS Group Limited (the Company) in any jurisdiction in which it would be unlawful. In particular, this document may not
Slide 24: International Offer Restrictions (Cont'd)
NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES INTERNATIONAL OFFER RESTRICTIONS (CONT’D) United Kingdom For personal use only Neither this document nor any other document relating to the offer has been delivered for approval to the Financial Conduct Authority in the United